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Antipsychotic Adherence, Switching, and Health Care Service Utilization
Among Medicaid Recipients With Schizophrenia
Abstract
Objective: To evaluate health care resource utilization in patients with schizophrenia who continued newly
prescribed antipsychotic medications, compared with those switching to different treatments.
Methods: Adults with schizophrenia in the California Medicaid (MediCal) database who initiated treatment
with index medications in 1998–2001, were classified as having: 1) abandoned antipsychotic medications; 2)
switched to another medication; or 3) continued with the index antipsychotic, for up to 6 months after the
index date.
Results: Of 2300 patients meeting eligibility criteria, 1382 (60.1%) continued index medications, 480
(20.9%) switched, and 438 (19.0%) abandoned antipsychotic treatment. Utilization in several resource
categories occurred significantly more frequently among patients whose regimens were switched (vs those
continuing index medications). These included using psychiatric (24.2% vs 14.5%; P < 0.001) or
nonpsychiatric (31.5% vs 24.3%; P < 0.05) emergency services; being admitted to a hospital (10.6% vs 7.4%;
P < 0.05); making nonpsychiatric outpatient hospital visits (43.3% vs 36.4%; P < 0.05) or nonpsychiatric
physician visits (62.7% vs 56.4%; P < 0.05); and using other outpatient psychiatric (53.3% vs 40.7%; P <
0.001) or nonpsychiatric (82.7% vs 74.6%; P < 0.001) services.
Conclusions: Switching antipsychotic medications is associated with significantly increased health care
resource utilization (vs continuing treatment).
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Objective: To evaluate health care resource utilization in patients with schizophrenia who 
continued newly prescribed antipsychotic medications, compared with those switching to 
 different treatments.
Methods: Adults with schizophrenia in the California Medicaid (MediCal) database who 
 initiated treatment with index medications in 1998–2001, were classified as having: 1)  abandoned 
antipsychotic medications; 2) switched to another medication; or 3) continued with the index 
antipsychotic, for up to 6 months after the index date.
Results: Of 2300 patients meeting eligibility criteria, 1382 (60.1%) continued index medications, 
480 (20.9%) switched, and 438 (19.0%) abandoned antipsychotic treatment. Utilization in several 
resource categories occurred significantly more frequently among patients whose regimens were 
switched (vs those continuing index medications). These included using psychiatric (24.2% vs 14.5%; 
P , 0.001) or nonpsychiatric (31.5% vs 24.3%; P , 0.05) emergency services; being admitted to a 
hospital (10.6% vs 7.4%; P , 0.05); making nonpsychiatric outpatient hospital visits (43.3% vs 36.4%; 
P , 0.05) or nonpsychiatric physician visits (62.7% vs 56.4%; P , 0.05); and using other outpatient 
psychiatric (53.3% vs 40.7%; P , 0.001) or nonpsychiatric (82.7% vs 74.6%; P , 0.001) services.
Conclusions: Switching antipsychotic medications is associated with significantly increased 
health care resource utilization (vs continuing treatment).
Keywords: antipsychotics, drug therapy, resource use, treatment adherence
Introduction
Many patients with schizophrenia experience suboptimal treatment outcomes with their 
initially prescribed antipsychotic agent and require a clinically warranted medication 
switch.1–4 Although medication switches represent sound “rescue” options, they are also 
typically indicative of suboptimal treatment outcomes with the first therapy.5–8 Patients 
for whom psychotropic medications prove to be ineffective may experience worse or 
more prolonged symptoms, have more marked progression of their illness, and, in severe 
cases, harm themselves or others.9–11 However, the implications of such adverse treatment 
outcomes with respect to health care resource utilization are unclear. The objective of 
the present study was to compare health care resource  utilization among patients with 
 schizophrenia who switched to a different antipsychotic  medication, with resource utiliza-
tion among those who continued on their newly prescribed antipsychotic medication.
Methods
study design and population
This exploratory retrospective analysis evaluated a sample of patients from the MediCal 
administrative claims database treated during the period of October 1, 1998 through 
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September 30, 2001. MediCal is a large, prepaid health plan 
with an enrollment of approximately 8.5 million participants 
in 2001.12
The index date was the earliest date of an antipsychotic 
medication prescription for which there was no prescrip-
tion for the same medication in the preceding 90 days. 
Eligible patients were aged 18 to 50 years and continuously 
enrolled in Medicaid from 90 days before the index date 
until 180 days after the index date. In addition, patients were 
required to meet 1 of the following definitions of schizo-
phrenia: a) 1 inpatient or 2 or more outpatient claims with 
an  International  Classification of Diseases, Ninth Revision 
(ICD-9) diagnostic code of 295.xx in the year before the 
index date; or b) 1 outpatient claim with an ICD-9 diagnostic 
code of 295.xx before or on the index date and 1 or more 
claims with the same diagnostic code within 180 days of the 
index date. Eligible patients were also required to have initi-
ated a single index antipsychotic on the index date. Patients 
dually enrolled in Medicaid and Medicare were excluded 
because the MediCal database did not contain detailed claims 
on Medicare-covered inpatient hospitalizations.
Definitions and assessments
Patients were designated by medication start categories on the 
basis of prescriptions filled before the index date (Table 1). 
Patients with no antipsychotic prescriptions filled in the year 
preceding the index date were defined as new users; those 
who filled an antipsychotic prescription 91 to 365 days before 
the index date, but did not fill a prescription in the 90 days 
immediately preceding the index date, were defined as restart-
ers. Those who filled prescriptions for any  antipsychotic during 
the 90 days before the index date were defined as established 
users.
Prescription claims were tracked beginning on the index 
date to determine if patients continued their index medica-
tion, and these data were used to assign patients to outcome 
categories. “Continued” patients filled pharmacy claims for 
the index medication (alone or with  augmentation) during the 
reference period, defined as days 91 to 180 after the index 
date. “Switched” patients discontinued the index medication 
and switched to a nonindex antipsychotic, as documented by 
pharmacy claims during the reference period. “Abandoned” 
patients discontinued antipsychotics altogether (no antipsy-
chotic pharmacy claims) during the reference period. Medicaid 
service utilization was assessed for 180 days after the index 
date. Categories of service use included emergency room 
(ER) visits, inpatient hospitalizations, outpatient hospital care, 
physician visits, and other outpatient services. Service use for 
each of these categories was analyzed according to whether 
the service was coded as psychiatric or nonpsychiatric, with 
each patient categorized according to whether they did or 
did not use that type of service. We did not conduct analyses 
according to the intensity of service use by patients.
Baseline patient characteristics were determined retrospec-
tively for both the start and outcome categories.  High-intensity 
comorbidities were ascertained using the  diagnostic  categories 
defined in the Chronic Illness and  Disability Payment  System 
(CDPS), a diagnostic  classification system employed by 
Table 1 Patient characteristics by start categories
Start category P
New Restart Established New vs Restart New vs Established Restart vs 
Established
No. (%) 622 (27.0) 632 (27.5) 1046 (45.5) – – –
Age, mean (sD), y 36.7 (8.5) 37.1 (8.2) 37.2 (7.9) 0.363 0.273 0.953
gender, male, % 56.3 55.4 56.9 0.776 0.838 0.576
race/ethnicity, % 0.318 ,0.001 0.007
 White 46.3 44.0 49.0 – – –
 Black 25.4 23.9 18.2 – – –
 Unknown 24.8 29.4 31.6 – – –
 hispanic 2.1 1.6 0.6 – – –
 Other 1.4 1.0 0.6 – – –
comorbid conditions, mean (sD), % 3.9 (3.6) 5.1 (3.6) 5.8 (3.4) ,0.001 ,0.001 ,0.001
Patients with high intensity 19.9 26.3 34.1 0.007 ,0.001 0.001
comorbidity,a %
Patients with prior period 12.1 7.6 7.9 0.010 0.007 0.851
psychiatric er use, %
Patients with prior period 5.3 2.7 1.8 0.021 ,0.001 0.230
psychiatric hospital stay, %
aDetermined using categories defined in the Chronic Illness and Disability Payment System.13
Abbreviations: sD, standard deviation; er, emergency room.
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Medicaid to make  health-based payments.13 Diagnoses 
recorded in the medical claims are categorized by diagnostic 
category (eg, psychiatric, cardiovascular, cancer, diabetes) 
and within each diagnostic category, a ranking of intensity 
from very high to extra low based upon the  Medicaid costs 
associated with treating patients in that group. For example in 
the psychiatric category, schizophrenia is classified as high; 
bipolar affective disorder as medium; and other depression, 
panic disorder, and phobic disorder each as low. We defined 
high-intensity comorbidities as those with CDPS rankings of 
high or very high.”
statistical analyses
Chi-square analyses were conducted to compare proportions 
of patients utilizing health care services between start and 
outcome categories. Tests of significance were conducted at 
an a priori two-tailed α = 0.05.
results
Of 64,324 unique antipsychotic users during the study 
period, 3990 met the study inclusion criteria, and 2300 were 
Medicaid-only recipients eligible for the study. In all, 622 
(27.0%) patients were categorized as new users, 632 (27.5%) 
as restarters, and 1046 (45.5%) as established users.
Six months after the index date, 1382 (60.1%) patients 
continued on their index medication, 480 (20.9%) switched 
to another antipsychotic, and 438 (19.0%) abandoned 
 antipsychotic treatment (Table 2). As shown in Table 2, 
individuals who abandoned antipsychotic medications had a 
significantly different race/ethnic distribution than those who 
continued (P , 0.001) and those who switched (P = 0.001). 
The group who abandoned antipsychotic treatment included 
relatively more individuals categorized as black. It should 
be noted that all groups had over 25% listed as unknown. 
Patients who switched antipsychotic medications had a sig-
nificantly higher mean number of comorbid conditions versus 
those continuing (P , 0.001) and versus those abandoning 
(P = 0.001) index medications. Previous psychiatric ER 
visits were significantly more common among patients who 
abandoned antipsychotics compared to those who continued 
(P , 0.001) and those who switched (P = 0.007), respectively 
and among patients who switched antipsychotics compared to 
those who continued (P = 0.020). Similar to the prior psychi-
atric ER visit findings, those who abandoned antipsychotics 
experienced higher rates of previous psychiatric hospitaliza-
tions compared to those who continued (P = 0.005) and those 
who switched (P = 0.015), respectively.
Aggregate treatment outcome 
comparisons
As shown in Figure 1a, significantly higher proportions 
of patients who switched antipsychotic medications were 
admitted to any hospital (10.6% vs 7.4%; P , 0.05 vs those 
continuing), including medical admissions (8.1% vs 5.0%; 
P , 0.05) but not psychiatric admissions.
Individuals who switched antipsychotics were also sig-
nificantly more likely to use a range of outpatient health care 
services, with the pattern for those who abandoned differing 
Table 2 Patient characteristics by outcome categories
Outcome category P
Switched Continued Abandoned Switched vs 
Continued
Switched vs 
Abandoned
Continued vs 
Abandoned
No. (%) 480 (20.9) 1382 (60.1) 438 (19.0) – – –
Age, mean (sD), y 36.6 (8.0) 37.1 (8.1) 37.3 (8.4) 0.257 0.221 0.689
gender, male, % 52.7 57.1 57.8 0.096 0.127 0.843
race/ethnicity, % 0.970 0.001 ,0.001
 White 48.0 48.7 40.3 – – –
 Black 18.6 19.5 32.3 – – –
 Unknown 30.9 29.7 25.6 – – –
 hispanic 1.5 1.2 1.1 – – –
 Other 1.0 0.9 0.7 – – –
comorbid conditions,mean (sD), % 5.7 (3.5) 4.9 (3.6) 4.9 (3.7) ,0.001 0.001 0.869
Patients with high intensity 30.6 27.7 26.7 0.240 0.188 0.667
comorbidity,a %
Patients with prior period 9.8 6.5 15.8 0.020 0.007 ,0.001
psychiatric er use, %
Patients with prior period 2.3 2.5 5.5 0.866 0.0145 0.005
psychiatric hospital stay, %
Abbreviations: sD, standard deviation; er, emergency room.
aDetermined using categories defined in the Chronic Illness and Disability Payment System.13
 Patient Preference and Adherence 2010:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
266
Noordsy et al
by whether it was ER-related or not (Figure 1b). Patients 
who switched and those who abandoned  antipsychotics 
used the ER significantly more frequently than those who 
continued, regardless of whether the ER visit was categorized 
as  psychiatric or medical. With the exception of outpatient 
 psychiatric hospital visits, where no significant differences 
were observed, the general pattern for the remaining  outpatient 
service categories was switching patients having the highest 
rate of service use, followed by those who continued and 
those who abandoned having the lowest rates of service use. 
Figure 1a inpatient hospitalization according to antipsychotic treatment outcome.
Inpatient hospitalization by AP treatment outcome
Switch vs Continue 
Switch vs Abandon 
* *
Continue vs Abandon
*P < 0.05;  **P < 0.01;  ***P < 0.001
0%
3%
6%
9%
12%
15%
All Psych Other
Switched Continued Abandoned
Type of hospital admission
A
d
m
it
te
d
 in
 6
 m
o
n
th
s 
p
o
st
-i
n
d
ex
 d
at
e
n = 480 n = 1,382 n = 438
Figure 1b Outpatient service use according to antipsychotic treatment outcome.
Outpatient service utilization by AP treatment outcome
Sw vs Con *** * ** * *** ***
Sw vs Abn ** *** *** *** ***
Con vs Abn ** *** *** *** *** ***
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Psych Med Psych Med Psych Med Psych Other
ER use Outpatient hospital Outpatient physician Other outpatient
Switched Continued Abandoned
U
se
 in
 6
 m
o
n
th
s 
p
o
st
-i
n
d
ex
 d
at
e
n = 480 n = 1,382 n = 438
*P < 0.05;  **P < 0.01;  ***P < 0.001
Patient Preference and Adherence 2010: 4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
267
 Antipsychotic adherence
All of these comparisons were statistically significant with 
the exception of continued versus abandoned in the medical 
outpatient hospitalization and switched versus continued in 
the psychiatric outpatient physician categories.
Treatment outcome comparisons by 
medication start type
New antipsychotic users
As shown in Figure 2a, patients who switched antipsychotic 
medications were in general more likely to utilize health 
care resources than their counterparts who continued on 
their index medications. Both ER-use categories, medical 
outpatient hospital visits, other outpatient physician, and 
other outpatient visits were all significant. The only switched 
versus abandoned comparison which reached significance 
was for other outpatient psychiatric visits which were higher 
among those who switched. Patients who abandoned were 
significantly more likely to use the ER (for both psychiatric 
and medical types of visits) and were also significantly more 
likely to experience a medical inpatient hospitalization than 
were those who continued.
restarting antipsychotic users
As shown in Figure 2b, restarting patients who switched 
 medications experienced signif icantly higher rates of 
 psychiatric ER use and both psychiatric and other outpatient 
service use compared to those who continued. These 3 service 
categories were also significantly higher in patients who 
switched compared to the patients who abandoned, as were 
medical inpatient hospitalization and medical outpatient hos-
pital services. Compared to those who abandoned, patients 
who continued their antipsychotics utilized significantly 
higher rates of medical outpatient hospital services and both 
psychiatric and other outpatient services.
established antipsychotic users
As shown in Figure 2c, established patients who switched 
medications experienced higher rates of psychiatric ER use 
and psychiatric other outpatient services compared to those 
who continued. Compared to those who abandoned, patients 
who switched also experienced higher rates of medical 
outpatient services, other outpatient physician services and 
both other and psychiatric other outpatient services. Patients 
who continued their antipsychotics utilized more medical 
outpatient physician and medical other outpatient services 
compared to those who abandoned. Abandoned patients uti-
lized comparable rates of ER services to those who switched; 
however, there was a small sample size in this cohort.
Discussion
In this retrospective administrative claims database  analysis, 
patients who switched from their index medication to a 
different antipsychotic medication within 6 months were 
significantly more likely to use a number of health care 
Service utilization by AP treatment outcome
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Figure 2a health care service utilization according to antipsychotic treatment outcome: new users. in 622 patients with available data.
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resources, including making ER visits and being  hospitalized, 
compared with their counterparts who continued on their 
index  antipsychotic medications. It is unclear whether 
the greater resource use observed among individuals who 
switched medications is a downstream consequence of the 
switch, a function of baseline differences in severity, or some 
combination of the two. The greater number of comorbid 
conditions and higher rates of prior psychiatric ER use 
among switchers compared to those who continue, suggests 
that baseline severity is an important contributor to the 
higher use of services in the outcome period. Rapid changes 
in antipsychotic treatment may result from a poor match 
Service utilization by AP treatment outcome
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Figure 2c health care utilization according to antipsychotic treatment outcome: established users. in 1,046 patients with available data.
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between patient and medication (ie, inadequate response or 
intolerability of side effects), erratic clinical decision making, 
erratic patient behavior, poorly integrated accessible systems 
of care, difficulties with access to care, and/or the cost of care 
(including medication copayments).
Patients who switched antipsychotic medications were 
more likely to use a number of health care services,  including 
hospitalization in particular. Some general  medical service 
utilization could be related to management of medication side 
effects. It is not clear why switching antipsychotic  medications 
was associated with more frequent  hospitalization for 
 nonpsychiatric conditions. However, these findings are 
broadly consistent with higher rates of acute relapses into 
active psychosis requiring intensive or emergent care in 
patients who discontinue treatment. Such patients may 
experience substantial medical complications or physical 
injury resulting from acute psychotic relapses with attendant 
 deficits in judgment, including suboptimal self-care of  medical 
conditions; dangerous behavioral responses to delusions; 
agitation;  violence; being victimized; and/or making suicide 
attempts.10,11 The distinction between psychiatric and medical 
service use is somewhat artificial and subject to the accuracy 
with which the reason(s) for the visit is coded.
Similar to patients who switched, those who abandoned 
their index antipsychotic also utilized more ER services than 
those who continued. For the majority of other services, 
however, abandoned patients utilized fewer resources than 
both those who continued and those who switched. One 
possible explanation for this finding is that patients who 
abandon their medication may be poorly engaged in  proactive 
psychiatric care.
Although smaller sample sizes in some of the cohorts 
limited the ability to draw definitive conclusions, it is worth-
while to examine differences in resource utilization patterns 
among the new, restarting, and established patient cohorts. 
ER Use: The new and established cohorts had very similar 
patterns of ER use. For both psychiatric and medical ER 
visits, those who switched and those who abandoned their 
index antipsychotic each used the ER more frequently than 
those who continued. Among restarting users, however, those 
who switched antipsychotics used the ER more frequently 
than both other groups.
Non-er outpatient services
Among established users, those who switched used outpatient 
services at least as frequently as those who continued and 
generally more frequently than those who abandoned. Among 
restarting antipsychotic users, however, switchers tended to 
use services most frequently, followed by those who continue 
and finally those who abandon. Among new antipsychotic 
users, those who switched used outpatient services with the 
greatest frequency in many categories. Unlike the restarting 
and established cohorts, however, service use for the aban-
doned group was often equivalent to that of the cohort who 
continued. Event rates ,10% for inpatient hospitalization 
made it difficult to discern a clear pattern.
Compared with their counterparts who continued on their 
index medications, patients who switched had  significantly 
more comorbid conditions at baseline and were  significantly 
more likely to have previously visited the ER. Consequently, it 
is unclear whether the higher rate of ER use among  switchers 
during the follow-up period represented a  continuation of the 
previous trend, a consequence of the medication switch, or 
some combination of these factors. Regardless of the reason, 
the increased use of these  medical services warrants close 
inspection, and future research should seek to characterize 
the proportion of ER service use  specifically attributable to 
switching.
Future studies are also needed to further evaluate the 
actual costs and cost-effectiveness of switching antipsychotic 
treatments. Perhaps not surprisingly, one recent post-hoc 
analysis of an open-label study concluded that  switching 
from one atypical antipsychotic to another because of 
inadequate efficacy or tolerability resulted in quality-of-life 
benefits (increased health utilities) and was projected to 
be cost effective.14 In contrast to other pharmacoeconomic 
analyses of schizophrenia treatments,15–18 the present study 
estimated health care costs indirectly via rates of health care 
resource utilization and did not capture health and other care 
not covered by Medicaid. These include medications  during 
inpatient treatment, as well as privately paid treatment, 
charity care, family care, and shelter care. As noted in the 
Methods, this study did not distinguish between  individuals 
using a particular service once and those with multiple 
visits or prolonged inpatient stays. Such an examination is 
necessary to assess the full economic impact of switching 
antipsychotics. The present study also compared health care 
utilization among patients switching (vs those continuing 
or abandoning) any antipsychotic medication; however, 
there may be differences in treatment adherence between 
individual antipsychotic agents.19
Other potential limitations of this study include its: 
1) retrospective and exploratory nature; 2) limited follow-up 
period (6 months); and 3) definition of continued treatment 
adherence on the basis of prescriptions filled, which are not 
necessarily accurate barometers of actual medication use. 
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As in other exploratory analyses, data were not adjusted for 
multiple comparisons. Further, an observational study cannot 
exclude potential biases resulting from unmeasured and other 
confounders. One potential confound is an imbalance of 
established antipsychotic medication users (45.5% of eligible 
patients); these users had significantly more comorbid condi-
tions than new users or restarters, and patients switching medi-
cations also had significantly more comorbidities than those 
who continued on, or abandoned, their index medications. It is 
possible that some of these comorbidities are related to medica-
tion side effects that may have motivated either the index or 
the subsequent antipsychotic medication change.
In many administrative claims database analyses such as 
this one, baseline patient-level data and on-treatment clinical 
information are limited. For example, in the present analysis, 
data on race/ethnicity were not available for approximately 
25% of participants. On the basis of a limited baseline period 
of 1 year before the index date and an average patient age 
of 37 years, it is unlikely that all patients in the “new-user” 
category were actually completely treatment naïve.
Given limited patient-level data, the data also could not 
be rigorously analyzed according to the reason for treatment 
discontinuation (eg, suboptimal efficacy, tolerability), which 
can influence health care resource utilization. By predefined 
eligibility criteria, the age at the index date ranged from 
18 to 50 years to exclude children, adolescents, and patients 
with dementia. Thus, our findings may not be generalizable 
to these patient segments. Our analysis was also based on 
Medicaid data from a single state (California) and hence 
may not be representative of the overall Medicaid popula-
tion with schizophrenia. Our findings are also not necessarily 
generalizable to the overall US schizophrenia population 
and may not apply to dual-eligible Medicaid recipients with 
schizophrenia. In light of these considerations, our results 
need to be further evaluated in larger, longer-term prospec-
tive studies conducted in naturalistic clinical settings and 
involving more heterogeneous patient populations.
Because our evaluation period was limited to days 91 to 
180 after the index date, it is not possible to conclude that all 
patients defined as having abandoned therapy did not actually 
obtain other forms of care at a later date. On the other hand, 
our 90-day reference period to define medication abandon-
ment was longer than has been reported in other analyses. 
Two previous administrative claims studies reported increased 
rates of hospitalization with gaps as short as 10 days.20,21 
We selected a 90-day refill gap to reduce the number of 
individuals misclassified as having abandoned antipsychotic 
treatment. However, one possible consequence of this 
 decision is that some individuals classified as having switched 
 antipsychotics in our study, would have been  considered as 
having a  clinically  significant gap (ie, abandoning therapy) 
in other studies.  Previous  studies have also demonstrated 
higher  hospitalization rates  associated with longer  medication 
gaps.20 Therefore, it is  possible that differences in service 
use between those  switching  antipsychotic medications 
or continuing their index medications in the present study 
might have been smaller if our analysis had employed a 
shorter  reference period to define abandonment. To the extent 
that both  medication switching and abandonment represent 
 suboptimal  medication treatment outcomes, however, this 
distinction may be less critical.
Conclusion
Patients who switch antipsychotic treatments experience 
 significantly increased health resource utilization compared 
with their counterparts remaining on their initial  medications. 
Future studies are needed to confirm these findings and  identify 
potential baseline or on-treatment predictors of favorable 
treatment responses, in order to minimize adverse human and 
economic outcomes of switching.
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